Acromegaly Market - A Global and Regional Analysis Focus on Drug Class, and Regional Analysis Analysis and Forecast

  2.1Overview
  2.2Somatostatin Analogues (SSAs)
  2.3Growth Hormone Receptor Antagonists (GHRAs)
  2.4Others
 

  3.1North America
     3.1.1Market Dynamics
          3.1.1.1Impact Analysis
     3.1.2Market Sizing and Forecast
3.1.2.1North America Acromegaly Market (by Drug Class)
3.1.2.2North America Acromegaly Market (by Country)
3.1.2.2.1U.S.
3.1.2.2.2Canada
  3.2Europe
     3.2.1Market Dynamics
          3.2.1.1Impact Analysis
          3.2.2Market Sizing and Forecast
               3.2.2.1Europe Acromegaly Market (by Drug Class)
               3.2.2.2Europe Acromegaly Market (by Country)
                      3.2.2.2.1U.K.
                      3.2.2.2.2Germany
                      3.2.2.2.3France
                      3.2.2.2.4Italy
                      3.2.2.2.5Spain
                      3.2.2.2.6Rest-of-Europe
3.3Asia-Pacific
  3.3.1Market Dynamics
       3.3.1.1Impact Analysis
  3.3.2Market Sizing and Forecast
       3.3.2.1Asia-Pacific Acromegaly Market (by Drug Class)
       3.3.2.2Asia-Pacific Acromegaly Market (by Country)
              3.3.2.2.1Japan
              3.3.2.2.2China
              3.3.2.2.3India
              3.3.2.2.4Australia
              3.3.2.2.5South Korea
              3.3.2.2.6Rest-of-Asia-Pacific
  3.4Latin America
     3.4.1Market Dynamics
          3.4.1.1Impact Analysis
     3.4.2Market Sizing and Forecast
          3.4.2.1Latin America Acromegaly Market (by Drug Class)
          3.4.2.2Latin America Acromegaly Market (by Country)
                 3.4.2.2.1Brazil
                 3.4.2.2.2Mexico
                 3.4.2.2.3Rest-of-Latin America
 3.5Rest-of-the-World
    3.5.1Market Dynamics
    3.5.2Market Size and Forecast
         3.5.2.1Rest-of-the-World Acromegaly Market (by Drug Class)

  4.1Competitive Benchmarking
  4.2Competitive Landscape
     4.2.1Key Strategies and Developments by Company
          4.2.1.1Funding Activities
          4.2.1.2Mergers and Acquisitions
          4.2.1.3Regulatory Approvals
          4.2.1.4Partnerships, Collaborations and Business Expansions
     4.2.2Key Developments Analysis
  4.3Company Profiles
     4.3.1Novartis AG
          4.3.1.1Company Overview
          4.3.1.2Product Portfolio
          4.3.1.3Target Customers/End Users
          4.3.1.4Analyst View
     4.3.2Sun Pharmaceutical Industries Ltd
          4.3.2.1Company Overview
          4.3.2.2Product Portfolio
          4.3.2.3Target Customers/End Users
          4.3.2.4Analyst View
     4.3.3Ipsen Pharma
          4.3.3.1Company Overview
          4.3.3.2Product Portfolio
          4.3.3.3Target Customers/End Users
          4.3.3.4Analyst View
          4.3.4Chiasma, Inc.
               4.3.4.1Company Overview
               4.3.4.2Product Portfolio
               4.3.4.3Target Customers/End Users
               4.3.4.4Analyst View
               4.3.5Peptron, Inc.
                    4.3.5.1Company Overview
                    4.3.5.2Product Portfolio
                    4.3.5.3Target Customers/End Users
                    4.3.5.4Analyst View
                    4.3.6Crinetics Pharmaceuticals Inc.
                         4.3.6.1Company Overview
                         4.3.6.2Product Portfolio
                         4.3.6.3Target Customers/End Users
                         4.3.6.4Analyst View
                    4.3.7Camurus
4.3.7.1Company Overview
4.3.7.2Product Portfolio
4.3.7.3Target Customers/End Users
4.3.7.4Analyst View
                    4.3.8Ionis Pharmaceuticals, Inc.
                         4.3.8.1Company Overview
                         4.3.8.2Product Portfolio
                         4.3.8.3Target Customers/End Users
                         4.3.8.4Analyst View
                    4.3.9Dauntless Pharmaceuticals
                         4.3.9.1Company Overview
                         4.3.9.2Product Portfolio
                         4.3.9.3Target Customers/End Users
                         4.3.9.4Analyst View
                    4.3.10Immunwork, Inc.
                          4.3.10.1Company Overview
                          4.3.10.2Product Portfolio
                          4.3.10.3Target Customers/End Users
                          4.3.10.4Analyst View
                    4.3.11Cipla
                          4.3.11.1Company Overview
                          4.3.11.2Product Portfolio
                          4.3.11.3Target Customers/End Users
                          4.3.11.4Analyst View
                    4.3.12Teva Pharmaceutical Industries Ltd.
                          4.3.12.1Company Overview
                          4.3.12.2Product Portfolio
                          4.3.12.3Target Customers/End Users
                          4.3.12.4Analyst View

5.Research Methodology

Figure: Global Acromegaly Market, Market Overview
Figure: Global Acromegaly Market, Epidemiological Analysis, U.S.
Figure: Global Acromegaly Market, Epidemiological Analysis, EU5
Figure: Global Acromegaly Market Coverage
Figure: Global Acromegaly Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Acromegaly Market, Competitive Landscape, January 2022-April 2025